Skip to main content

Table 1 Baseline stroke risk stratification and recommended antithrombotic therapy for patients with nonvalvular atrial fibrillation

From: A randomized trial to assess the impact of an antithrombotic decision aid in patients with nonvalvular atrial fibrillation: the DAAFI trial protocol [ISRCTN14429643]

Strata Clinical factors Estimated bi-annual stroke risk (%) 2001 ACCP recommended therapy [5]
Low Age < 65 years, no history of hypertension, heart failure or reduced LVEF, or prior systemic emboli 2 ASA
Moderate-low Age 65–75 years, no history of hypertension, heart failure or reduced LVEF, or prior systemic emboli 4 ASA or warfarin
Moderate-high Age 65–75 years, no history of hypertension, heart failure or reduced LVEF, or prior systemic emboli but have diabetes mellitus or coronary artery disease 6 Warfarin (target INR 2–3)
High Age ≤ 75 years with history of hypertension or heart failure/reduced LVEF OR age > 75 years with no history of hypertension, heart failure or reduced LVEF, or prior systemic emboli 12 Warfarin (target INR 2–3)
Very High Age > 75 years with history of hypertension or heart failure/reduced LVEF OR any age with prior emboli 20 Warfarin (target INR 2–3)
  1. ACCP = American College of Chest Physician LVEF = left ventricular ejection fraction ASA = acetylsalicylic acid